UPDATED ON 10/20/2022

The factors effecting the IP Valuation of LPBI Group are described in:

• Portfolio of IP Assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

 

• 2.0 LPBI is a Very Unique Organization – Section Valuation & Stream of Innovations

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

 

• 2022 Update from LPBI Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

 

• 2.0 LPBI, Strategy #2: Blockchain Transactions Network Ecosystem

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

 

• NFT: Redefined Format of IP Assets

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

 

• Audio English-Spanish: BioMed e-Series          

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

 

UPDATED on 8/30/2022

LPBI Group’s elevator Pitch

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/ 

LPBI Group’s ventures need to be positioning us as two ventures:

• 1.0 LPBI, 2012 – 2020 – a scientific publisher
• 2.0 LPBI Group, 2021 – 2025 – a software powerhouse with four missions (pipelines)

2022-2023 Elevator Pitch needs to incorporate the following achieved Milestones/accomplishments to date

This Elevator Pitch for 1.0 LPBI, 2012 – 2020 does not include all the PROGRESS accomplished at 2.0 LPBI Group, 2021 – 2025:

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/

 

Status of 2.0 LPBI Group’s four pipelines is as follows:

 

Mission #1: NLP (completed): 

NEW GENRE NLP

• Genomics Volume Three and 
• NEW GENRE Cancer Volume One 

both include the Text analysis of the respective original volume processed by NLP algorithms: What are the results and the Domain Knowledge Expert interpretation

 

• 2.0 LPBI Group’s Mission #1 (Text analysis with AI) 

Series B: Genomics

New volume 

NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP).  It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

 

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

• Original Volume One: Cancer Biology and Genomics for Disease Diagnosis

On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

• NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART A:

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B:

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

PART C:

The Editorials of the original e-Book in English in Audio format

 

Mission #2: Blockchain & NFT – work-in-progress

• Erich is the Lead 
• Results of DB Schema Phase 1 will be presented on 9/13 in the Board meeting

Please review

Blockchain Infrastructure we are developing for content monetization [2.0 LPBI Group’s Mission #2]

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

and 

NFT minting of our IP [2.0 LPBI Group’s Mission #2]

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

 

Mission #3: Completion of the Spanish translation of eTOCs for all our 18 BioMed e-Series 

• Mission #3 (Spanish Translation and RE-publishing 18 books as NEW GENRE BioMed e-Series: 

Audio English-Spanish: BioMed e-Series

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

Please review

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

Mission #4: Galectins – Drug discovery with software [2.0 LPBI Group’s Mission #4]

– work-in-progress 

• Dr. Williams is the Lead  

Please review

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

 

UPDATED on 8/5/2022

The Multimedia new format creates a 

NEW GENRE OF SCIENTIFIC BOOK

Each NEW book has three parts:

PART A: The eTOCs in Spanish in Audio format [Spanish Text-To-Spanish Sound]

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format [English Text-To-English Sound]

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

Date of SOUND upload to Amazon, tba

SEE ALL TEXTS in the links, below

 

Scientific Books e-Series

New Genre: Audio English-Spanish

Spanish Translation performed by

Montero Language Service, Madrid, Spain 

 

• NEW GENRE Audio English-Spanish – Series A: e-Books on Cardiovascular Diseases

 

Series A: Six volumes – e-Books on Cardiovascular Diseases NEW GENRE Audio English-Spanish

http://www.amazon.com/dp/B00DINFFYC

Original book on com since 6/21/2013

• NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms – Series A: Volume 1

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-one-perspectives-on-nitric-oxide-in-disease-mechanisms-series-a-volume-1/

 

http://www.amazon.com/dp/B018Q5MCN8

Original Book on Amazon.com since 11/30/2015

• NEW GENRE Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: Series A, Volume 2

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-two-cardiovascular-original-research-cases-in-methodology-design-for-content-co-curation-series-a-volume-2/

 

http://www.amazon.com/dp/B018PNHJ84

Original book on Amazon.com since 11/29/2015

• NEW GENRE Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics – Series A, Volume 3

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-three-etiologies-of-cardiovascular-diseases-epigenetics-genetics-and-genomics-series-a-volume-3/

 

http://www.amazon.com/dp/B019UM909A

Original book on Amazon.com since 12/26/2015

• NEW GENRE Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine – Series A, Volume 4

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-four-therapeutic-promise-cardiovascular-diseases-regenerative-translational-medicine-series-a-volume-4/

 

https://www.amazon.com/dp/B07MGSFDWR

Original book on Amazon.com since 12/23/2018

• NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/

 

https://www.amazon.com/dp/B07MKHDBHF

Original book on Amazon.com since 12/24/2018

• NEW GENRE Volume Six: Interventional Cardiology for Disease Diagnosis and and Cardiac Surgery for Condition Treatment – Series A, Volume 6

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-six-interventional-cardiology-for-disease-diagnosis-and-and-cardiac-surgery-for-condition-treatment-series-a-volume-6/

 

 

• NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research

 

Series B: Frontiers in Genomics Research NEW GENRE Audio English-Spanish

http://www.amazon.com/dp/B018DHBUO6

On Amazon.com since 11/23/2015

• Original Volume One: Genomics Orientations for Personalized Medicine
• NEW GENRE Volume One: Genomics Orientations for Personalized Medicine 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-one-genomics-orientations-for-personalized-medicine-series-b-volume-1/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

 

https://www.amazon.com/dp/B08385KF87

On Amazon.com since 12/28/2019

• Original Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology
• New Genre Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-two-latest-in-genomics-methodologies-for-therapeutics-gene-editing-ngs-and-bioinformatics-simulations-and-the-genome-ontology-series-b-volume-2/

PART A:

A.1: The eTOCs in Spanish in Audio format AND

A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B: The graphical results of Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format – IS ISSUED AS A STANDALONE VOLUME: Volume Three  NEW GENRE Volume Three in Series B.

PART C: The Editorials of the original e-Books in English in Audio format

• Volume Three did not exist in the Original BioMed e-Series, Series B: Frontiers in Genomics Research
• During production it was known as PART B of Genomics, Volume Two to be published in the NEW GENRE e-Series B. It was thought to be included in Volume Two. Due to number of plots involved, a standalone volume for NLP Results and Interpretation was born, aka, Volume Three.

 

• NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP).  It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

 

• NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology

 

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

http://www.amazon.com/dp/B013RVYR2K

On Amazon.com since 12/28/2019

• Original Volume One: Cancer Biology and Genomics for Disease Diagnosis
• NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART A:

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B:

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

PART C:

The Editorials of the original e-Book in English in Audio format

 

http://www.amazon.com/dp/B071VQ6YYK

On Amazon.com since 5/18/2017

• Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
• NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-two-cancer-therapies-metabolic-genomics-interventional-immunotherapy-and-nanotechnology-in-therapy-delivery-series-b-volume-2%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Book in English in Audio format

 

• NEW GENRE Audio English-Spanish – Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology

 

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology – NEW GENRE Audio English-Spanish – Volumes 1,2,3,4.

http://www.amazon.com/dp/B012BB0ZF0

On Amazon.com since 7/21/2015

• Original Volume One: Metabolic Genomics & Pharmaceutics
• NEW GENRE Volume One: Metabolic Genomics & Pharmaceutics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-one-metabolic-genomics-pharmaceutics-series-d-volume-1%ef%bf%bc/

 

https://www.amazon.com/dp/B075CXHY1B

On Amazon.com since September 4, 2017

• Original Volume Two in the Volume Two and Three combined format: Infectious Diseases and Therapeutics
• NEW GENRE Volume Two: Infectious Diseases and Therapeutics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-two-infectious-diseases-and-therapeutics-series-d-volume-2-%ef%bf%bc/

 

https://www.amazon.com/dp/B075CXHY1B

On Amazon.com since September 4, 2017

• Original Volume Three in the Volume Two and Three combined format: The Immune System and Therapeutics
• NEW GENRE Volume Three:  The Immune System and Therapeutics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-three-the-immune-system-and-therapeutics-pharmaceutics-series-d-volume-3-%ef%bf%bc/

 

http://www.amazon.com/dp/B08VTFWVKM

On Amazon.com  since February 2, 2021

• Original Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types
• NEW GENRE Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-four-human-reproductive-system-genomic-endocrinology-and-cancer-types-pharmaceutics-series-d-volume-4-%ef%bf%bc/

 

 

• NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine  

 

Series E: Patient-Centered Medicine & Precision Medicine – NEW GENRE Audio English-Spanish

 

https://www.amazon.com/dp/B076HGB6MZ

On Amazon.com since 10/16/2017

• Original Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
• NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-one-the-voices-of-patients-hospitals-ceos-health-care-providers-caregivers-and-families-personal-experience-with-critical-care-and-invasive-medical-procedures-series-e-vo/

 

https://www.amazon.com/dp/B078313281

On Amazon.com since12/9/2017

• Original Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
• NEW GENRE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-two-medical-scientific-discoveries-for-the-21st-century-interviews-with-scientific-leaders-series-e-volume-2%ef%bf%bc/

 

http://www.amazon.com/dp/B019VH97LU

On Amazon.com since 12/27/2015

• Original Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
• NEW GENRE Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-three-milestones-in-physiology-discoveries-in-medicine-and-genomics-series-e-volume-3%ef%bf%bc/

 

https://www.amazon.com/dp/B078QVDV2W

On Amazon.com since 12/30/2017

• Original Volume Four: Medical 3D BioPrinting – The Revolution in Medicine
• NEW GENRE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-four-medical-3d-bioprinting-the-revolution-in-medicine-series-e-volume-4%ef%bf%bc/

 

HAPPY TO SHARE WITH YOU THIS MILESTONE

 

 

UPDATED on 7/22/2022

NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine  

Series E: Patient-Centered Medicine & Precision Medicine – NEW GENRE Audio English-Spanish

>>>>>> 

• Original Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

On Amazon.com since 10/16/2017

https://www.amazon.com/dp/B076HGB6MZ

• NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-one-the-voices-of-patients-hospitals-ceos-health-care-providers-caregivers-and-families-personal-experience-with-critical-care-and-invasive-medical-procedures-series-e-vo/

This volume has the following parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>>>> 

• Original Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders

On Amazon.com since12/9/2017

https://www.amazon.com/dp/B078313281

• NEW GENRE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-two-medical-scientific-discoveries-for-the-21st-century-interviews-with-scientific-leaders-series-e-volume-2%ef%bf%bc/

This volume has the following three parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>>>> 

• Original Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics

On Amazon.com since 12/27/2015

http://www.amazon.com/dp/B019VH97LU

• NEW GENRE Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-three-milestones-in-physiology-discoveries-in-medicine-and-genomics-series-e-volume-3%ef%bf%bc/

This volume has the following three parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>>>> 

• Original Volume Four: Medical 3D BioPrinting – The Revolution in Medicine

On Amazon.com since 12/30/2017

https://www.amazon.com/dp/B078QVDV2W

• NEW GENRE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-four-medical-3d-bioprinting-the-revolution-in-medicine-series-e-volume-4%ef%bf%bc/

This volume has the following three parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

 

UPDATED on 7/7/2022

Explanation on Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C

https://pharmaceuticalintelligence.com/2022/07/07/results-of-medical-text-analysis-with-natural-language-processing-nlp-presented-in-lpbi-groups-new-genre-edition-nlp-on-genomics-content-standalone-volume-in-series-b-and-nlp-on-cancer-co/

 

WORKFLOW for a Eight-Steps Medical Text Analysis Operation using NLP on LPBI Medical and Life Sciences Content

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/

 

UPDATED on 7/6/2022

 

UPDATED on 7/2/2022

 

UPDATED on 6/28/2022

Cancer, Volume 1: NLP results – 12 Hypergraph Plots and 12 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-volume-1-nlp-results-12-hypergraph-plots-and-12-tree-diagram-plots-by-madison-davis/

This is a Subpage to 

• NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART B: The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

@@@@

• Genomics, Volume 2: NLP results – 38 or 39 Hypergraph Plots and 38 or 39 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/genomics-volume-2-nlp-results-38-or-39-hypergraph-plots-and-38-or-39-tree-diagram-plots-by-madison-davis/

This is a Subpage to 

• Genomics Volume 2, Results of Medical Text Analysis with Natural Language Processing (NLP) – PART B in NEW GENRE Series B, Volume 2

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

 

UPDATED on 6/23/2022

Series B, NEW GENRE Volumes 1,2 and Results of Medical Text Analysis with NLP

• NEW GENRE Volume One: Genomics Orientations for Personalized Medicine – Series B, Volume 1
• NEW GENRE Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology – Series B, Volume 2
• Genomics Volume 2, Results of Medical Text Analysis with Natural Language Processing (NLP) – PART B in NEW GENRE Series B, Volume 2 This book has a Subpage: 

Genomics, Volume 2: NLP results – 38 or 39 Hypergraph Plots and 38 or 39 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/genomics-volume-2-nlp-results-38-or-39-hypergraph-plots-and-38-or-39-tree-diagram-plots-by-madison-davis/

UPDATED on 6/7/2022

Series A, NEW GENRE Volumes 1,2,3,4,5,6

NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms – Series A: Volume 1

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-one-perspectives-on-nitric-oxide-in-disease-mechanisms-series-a-volume-1/

 

NEW GENRE Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: Series A, Volume 2

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-two-cardiovascular-original-research-cases-in-methodology-design-for-content-co-curation-series-a-volume-2/

 

NEW GENRE Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics – Series A, Volume 3

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-three-etiologies-of-cardiovascular-diseases-epigenetics-genetics-and-genomics-series-a-volume-3/

 

NEW GENRE Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-four-therapeutic-promise-cardiovascular-diseases-regenerative-translational-medicine-series-a-volume-4/

 

NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/

 

NEW GENRE Volume Six: Interventional Cardiology for Disease Diagnosis and and Cardiac Surgery for Condition Treatment – Series A, Volume 6

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-six-interventional-cardiology-for-disease-diagnosis-and-and-cardiac-surgery-for-condition-treatment-series-a-volume-6/

 

UPDATED on 6/6/2022

Audio English-Spanish: BioMed e-Series

• NEW GENRE Audio English-Spanish – Series A: e-Books on Cardiovascular Diseases
• NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research
• NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology
• NEW GENRE Audio English-Spanish – Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology
• NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine  

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

UPDATED on 5/24/2022

• 1.0 LPBI IP Asset Class I: Journal Articles by Top Authors

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2022/04/11/equity-sharing-calculation-a-scoring-system-for-authors-a-total-articles-single-author-and-multiple-authorsb-total-articles-views-and-c-authors-proportion-of-own-articles-views-in/

More details are found in

https://pharmaceuticalintelligence.com/2020/12/08/papers-citing-pharmaceuticalintelligence-com/

 

• LinkedIn 1st degree connections by Biotech Company Name and by Connections positions

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025

and

Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

 

UPDATED on 5/7/2022

Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and All Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON

Real Time coverage: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/05/07/tweets-at-wmif2022-by-pharma_bi-aviva1950-and-all-retweets-of-these-tweets-2022-world-medical-innovation-forum-gene-cell-therapy-may-2-4-2022/

 

2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON

https://pharmaceuticalintelligence.com/2022/05/01/2022-world-medical-innovation-forum-gene-cell-therapy-may-2-4-2022-boston-in-person/

 

Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare

https://pharmaceuticalintelligence.com/2022/05/09/lessons-on-the-frontier-of-gene-cell-therapy-the-disruptive-dozen-12-gct-breakthroughs-that-are-revolutionizing-healthcare/

UPDATED on 4/25/2022

TODAY, TEN years ago we on 4/25/2012 we published our 1^st article

TODAY, 4/25/2022 we have 6,135 articles

TODAY, we have 2,115,903 Views at all time

http://pharmaceuticalintelligence.com

 

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/

 

2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

 

 

 

 

UPDATED on 4/6/2022

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025 and Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

 

UPDATED on 3/30/2022

Tweet Collection of 2022 EmTechDigital @MIT, March 29-30, 2022

Tweet Author: Aviva Lev-Ari, PhD, RN

Selective Tweet Retweets for The Technology Review: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/04/02/tweet-collection-of-2022-emtechdigital-mit-march-29-30-2022/

 

UPDATED on 3/21/2022

Agenda overview: EmTech Digital & AI 2022, March 29-30, 2022

https://event.technologyreview.com/emtech-digital-2022/agenda-overview

Aviva will cover EmTech Digital & AI 2022, March 29-30, 2022 in REAL TIME

• on a PRESS PASS from MIT granted today.

Another e-Proceedings and Tweet Collection.

 

UPDATED on 3/12/2022

2022 Update from LPBI Group

Author & Curator: Aviva Lev-Ari, PhD, RN

2022 Update from LPBI Group

 

UPDATED on 3/3/2022

We are publishers of PharmaceuticalIntelligence.com  

February 3rd, 2022
Total # of Scientific Article Views	2,089.759
Total # of Global Scientific Comments	7,932
Total # of Categories – Journal Ontology	743
Total # of Tags	10,653
Total # of Scientific Articles	6,112

Top Author 2/3/2022	Total Views by AUTHOR, 2012-2022
2012pharmaceutical – Aviva Lev-Ari	508,457
Larryhbern – Dr. Larry	373,618
Sjwilliamspa – Dr. Williams	72,513
Tildabarliya – Tilda BarLiya	69,934
Dr. Sudipta Saha – Dr. Saha	39,088
Dror Nir – Dr. Nir	38,314
Demet Sag Ph.D. CRA GCP	20,030
Ritusaxena – Dr. Saxena	17,330
Gail S Thornton – PhD(c)	18,112
Irina Robu, PhD	10,208

UPDATED on 2/8/2022

Announcing LPBI Group’s SCIENCE SIDE – Monthly Virtual Lecture Series on Zoom

Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications

Presentation of Several Inventions of AI in Medical Applications (1) Cancer (2) Ultrasound and

Potential Collaboration & funding needs

LECTURE TITLE on 2/15/2022 11AM EST

“Biosensors in Oncology and Prematurity“

the prototype of a novel sensor for the detection of prematurity (nothing to do with uterine contractions) Prematurity is 9.8/100 pregnancies in US and a $22b expense in the first year of life.

LECTURE TITLE on 3/15/2022 11AM EST

AI Based Screening  and in Silico Genomic Diagnoses of Congenital Anomalies in Early Pregnancy

UPDATED on 2/7/2022

Announcing New Addition to LPBI Group in dual capacity: EAW & External Scientific Relations:

Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications

https://pharmaceuticalintelligence.com/contributors-biographies/experts-authors-writers-eaws/shraga-rottem-m-d-d-sc-expert-author-writer-external-scientific-relations-on-ai-in-medical-applications/

 

UPDATED on 12/6/2022

We announce that Pranith Rekala had joined LPBI Group’s Medical Text Analysis with NLP – Mission #1

Pranith Rekala, Research Assistant 2, Medical Text Analysis using NLP (Genomics Content, Project #1; Cancer Content, Project #2) and Molecular Design with Synthetic Biology Software (Project #3).

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/pranith-rekala-research-assistant-2-medical-text-analysis-using-nlp-genomics-content-project-1-cancer-content-project-2-and-molecular-design-with-synthetic-biology-software-project-3/

 

UPDATED on 1/17/2022

Today we issued a Certificate in Medical Text Analysis to Danielle Smolyar who Joined LPBI Group on 8/15/2020.

We are working now on PART B – NLP for Cancer, Volume 1 – New Genre e-Series 

UPDATED on 1/12/2022

There are FOUR points I wish you to take home FROM the five-hour Global Zoom Monthly Board Meeting on

1/11/2022, 11AM EST – 4PM EST

POINT #1:

1 to 7, below represent Frontiers of Compute Technologies in multiple domains where 2.0 LPBI Group had developed and is developing Intellectual Property.

1. We completed NLP on 2 major books – 4 are work-in-progress
2. Spanish audio and text for eTOCs of 18 books in Medicine
3. Books – 140,000 page download
4. Blockchain infrastructure – under development – Journal’s Ontology data schema in Knowledge graph in proof of concept stage
5. PROTACs with PRosettaC – Galectins Drug Discovery with synthetic biology software
6. Auction molecules on the Blockchain IT as NFT
7. Auction scientific curations articles on the Blockchain IT as NFT

POINT #2:

We had added to our esteemed group of External Business Relations:

Mr. Luis De La Cruz, Phoenix, AZ – BUSINESS EXECUTIVE, COMMUNITY ACTIVIST AND PHILANTHROPIST

• We will jointly pursuing the following FOUR initiatives that will be mutual beneficial

Exploration of LPBI Group potential contributions to several goals:

INITIATIVE #1:

A Documentary Film on Life Sciences

• We will schedule a BRAINSTORMING JOINT Zoom meeting to kick off IDEAS
• LPBI Group brings to the table the following resources:
• All IP Asset Classes of relevance to the Film https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

• LPBI Groups Available Podcasts

Type 1:       Podcasts about LPBI Group’s Scientists

·  Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-sudipta-saha-phd-interview-by-gail-s-thornton-phdc-narrators-voice-gail-s-thornton-phdc/

· Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

· Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-prof-marcus-w-feldman-phd-biology-department-stanford-university-interview-by-gail-s-thornton-phdc/

· Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/partners-in-health-and-biz-radio-interview-with-aviva-lev-ari-ph-d-r-n-stephen-williams-ph-d-and-irina-robu-ph-d-on-5-2019-on-topic-of-3d-medical-bioprinting-technology-a-revolution-in-med/

Type 2:        Podcasts of LPBI Group’s LIBRARY of 250 INTERVIEWS with Scientific Leaders

Archive for the ‘Interviews with Scientific Leaders’ Category

https://pharmaceuticalintelligence.com/category/interviews-with-scientific-leaders/

 

INITIATIVE #2:

Use of LPBI Group’s BioMed e-Series for Mission:Brain Foundation 

https://www.missionbrain.org/

Mr. Luis De La Cruz, is attempting to invite to our February 15, 2022, Dr. Alfredo Quinones, MD

 

 

• Dr. Alfredo Quinones MD Mayo Clinic Nuevo – surgeon is the director is this project to share the values of an outreach program for underserved/ disadvantaged communities is the USA.

https://youtu.be/eGCs2LHPtXM

• Dr Alfredo Quinones-Hinojosa – CNN interview (Short Version)

https://www.youtube.com/watch?v=tstfM-PBsNQ

·      Rhoda Goldman Health Lecture: Dr. Alfredo Quinones-Hinojosa

https://www.youtube.com/watch?v=22q7P6RIflk

 

INITIATIVE #3

• Proposal development for presentation to C.S. in Mexico Transfer of Ownership of LPBI Portfolio of IP https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

ALL Members of our External Business Relations and our Leadership will work on this proposal

 

INITIATIVE #4

• Spanish speaking countries – Market penetration for LPBI Group’s New Genre Scientific Books – Spanish eTOCs – 18 books in Medicine

A Meeting with Montero and GTO and Mr. De La Cruz

Marketing our NEW GENRE e-Series Books in SPANISH speaking countries

WE will be scheduling a Zoom Meeting with all the Parties

POINT #3:

Dr. Williams developed a methodology on HOW TO write Interpretation for NLP Results

• It was applied on Cancer, Volume 1
• It is been applied on Genomics Volume 2
• It will be applied on Genomics, Volume 1
• It will be applied on Cancer, Volume 2

POINT #4:

• Please Watch the Podcasts by Steve Wolfram on NLP and Blockchain
• Please Watch the Podcasts by Vitalik Buterin on Multiple Blockchains

https://pharmaceuticalintelligence.com/2-0-lpbi-calendar-of-zooms/

UPDATED on 1/9/2022

The following sources represent UPDATES on LPBI Group:

Slide deck as of 8/24/2021 – available

 

I published on our Journal:

• 2021 – A Year in Review

https://pharmaceuticalintelligence.com/2022/01/04/goal-attainment-scaling-record-2021-a-year-in-review/

I published on our Journal:

• Portfolio on Intellectual Property Assets:

2012-2020 – Ten IP Assets

2021-2025 – Four IP Assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

I published on our Journal:

2.0 LPBI: A Unique Organization

• Podcast and Text with graphs

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

• LPBI Group’s multiple technologies include the following:

1. We completed NLP on 2 major books of ours – 4 other books are in NLP test analysis process – work-in-progress
2. Spanish audio and text for eTOCs of 18 books in Medicine

https://lnkd.in/ekWGNqA

3. Bi-Lingual Spanish-English of eTOCs of these 18 Books
4. Editorials of each Book in English Audio
5. Above 1,2,3,4 – are included in a New Genre of Scientific Books Launched
6. Books in above URL in Blue enjoy – 140,000 page download
7. Blockchain infrastructure – under development – Journal’s Ontology data schema in Knowledge graph fluree.com format is in proof of concept stage
8. PROTACs with PRosettaC – Galectins Drug Discovery with synthetic biology software
9. Auction molecules on the Blockchain IT as NFT
10. Auction scientific curations articles on the Blockchain IT as NFT

1,5,7,8,9,10, above represent Frontiers of Compute Technologies in multiple domains where LPBI Group had developed and is developing IP.

UPDATED on 1/3/2022

Mission #1: Medical Text Analysis with Wolfram Language NLP

New Genre BioMed e-Series to include the following Book structure:

PART A: Book electronic Table of Contents (eTOCs) in Spanish: Audio Format and Bi-lingual eTOCs in Spanish-English: Text Format

PART B: (1) Results of Wolfram Language for Biological Sciences – Natural Language Processing (NLP), (2) Appendix: Code used for each plot, and (3) Interpretation of NLP Results by Domain Knowledge Expert

PART C: Original Book’s Editorials excerpt selections in English: Audio Format and Text

 

Text Analysis with NLP for the entire volume: Cancer Volume 1 was completed on 12/27/2021 by Satwik Sunnam

Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

Interpretation for NLP Results of Cancer, Volume 1 – is announced as Complete on 1/3/2022. Interpretation done by Dr. Williams

New Genre Book Template for Genomics, Volume 2, PART B: Text Analysis with NLP was completed by Madison Davis on 12/29/2021

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology On Amazon.com since 12/28/2019

https://www.amazon.com/dp/B08385KF87

Interpretation for NLP Results of Genomics, Volume 2 – started on 1/3/2022.

• Domain knowledge Expert Interpretation is done by Dr. Williams for Parts 2,3,4,7,8
• Domain knowledge Expert Interpretation is done by Prof. Feldman for Part 5
• Domain knowledge Expert Interpretation is done by Aviva Lev-Ari, PhD, RN for Part 1

 

UPDATED on 1/2/2022

Medical Text Analysis with Wolfram Machine Learning (ML) and Natural Language Processing (NLP) for LPBI Group’s

Genomics, Volume 2

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

is as of 1/2/2022 COMPLETE 

• The Book’s PART B is 244 pages without the forthcoming Plot interpretations
• without PART A: eTOCs Spanish Audio and Bi-Lingual Text
• without PART C: Editorials – English Text & Audio
• We need a PREFACE for the New Genre of Scientific Books

———————-@@@@@@@@@@@@@———————-

 

2021

 

UPDATED on 12/3/2021

UPDATED on 10/22/2021

How LPBI Group plans to use the Spanish Translation of its BioMed e-Series:  Cover page of 18  e-Books and electronic Table of Contents of these e-Books?

https://lnkd.in/ekWGNqA

In November 2021 – I will start to convert the Spanish eTOCs to Sound files and will start to publish

LPBI Group’s

Medical eBooks New Genre Edition !!!!

• Spanish in Audio format, 
• Bi-Lingual Text, 
• NLP, Results and Domain Knowledge Expert Interpretations, and
• English Editorials in Audio format

Application of LPBI Group’s New Genre Edition of Medical Books:

Each Series: A, B, C, D, E – ONE Volume per Series – 5 volumes in Total

• Series A: Six volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
• Series B: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
• Series C: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
• Series D: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
• Series E: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio

Each Volume: in each Series – 18 volumes in Total 

• Part A: Bi-Lingual eTOCs,
• Part B: NLP, Results and Domain Knowledge Expert Interpretations
• Part C: Editorials English Audio

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

https://www.amazon.com/dp/B08385KF87

http://www.amazon.com/dp/B08VTFWVKM

I am so excited about the

Medical eBooks New Genre Edition !!!!

UPDATED on 10/16/2021 

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/madison-davis-research-assistant-1-text-analysis-initiative/

It is with the highest OWE that I have issued today

LPBI’s first Cerficicate in Medical Text Analysis for COMPLETION OF 18 Months of Academic Training, the Completion of NLP of an entire book 

GENOMICS VOLUME 2

Latest in Genomics Methodologies for Therapeutics:

Gene Editing, NGS & BioInformatics,

Simulations and the Genome Ontology

2019

Volume Two

https://www.amazon.com/dp/B08385KF87

Deep Learning NLP

performed by

MADISON DAVIS

Thank you very much for completion of Genomics Volume 2 – This is a COLLOSAL accomplishment.

Genomics, Volume 2 will be LPBI’s 1^st e-Book in

LPBI’s NEW GENRE EDITION of Scientific Books with the following format

• Part A: eTOCs in Spanish AUDIO and Bi-Lingual Spanish and English TEXT – Text Source: ORIGINAL Book
• Part B: Deep Learning NLP by Madison Davis – Graphic Visualization
• Part C: Editorials in English AUDIO – Text Source: ORIGINAL Book

AFTER we finish PART B, above, I am advising Madison:

• to consider to start to work on Synthetic Biology Software for Molecular Design for Galectins 

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

• Starting a NEW Internship leading to a New Certificate in Synthetic Biology Software for Molecular Design for Galectins

Detailed description to be found on each Internship page, below

• Medical Text Analysis (Deep Learning NLP)
• IS, IT, CS and Data Science Internship
• Blockchain Knowledge Graph Database Design with Interface to Wolfram NLP
• Finance Internship: Financial Modeling
• Synthetic Biology Software for Drug Design in Glycobiology Internship
• Journalism and Marketing Communications in Pharmaceutical Media

I am encouraging all INTERNS to complete their assignments

• GET Certificate(s)
• Move to Another Internship – ALL ARE TUITION FREE

UPDATED on 10/7/2021

Tweets and Re-Tweets of Tweets by @pharma_BI  @AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021, #WMIF2021

https://pharmaceuticalintelligence.com/2021/10/07/tweets-and-re-tweets-of-tweets-by-pharma_biaviva1950-at-2021-virtual-world-medical-innovation-forum-mass-general-brigham-gene-and-cell-therapy-virtual-may-19-21-2021/

UPDATED on 10/4/2021

Tweets and Re-Tweets of Tweets by @pharma_BI  @AVIVA1950  at EmTech MIT 2021, #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/10/04/tweets-and-re-tweets-of-tweets-by-pharma_bi-aviva1950-at-emtech-mit-2021-emtechmit-9-28-to-9-30-2021%ef%bf%bc/

UPDATED on 10/2/2021

LPBI covered in Real Time the Virtual MIT Technology Review’s flagship event, September 28-30, 2021 – EmTech MIT 2021

• EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://event.technologyreview.com/emtech-mit-2021/agenda

https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

• Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

• Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/09/29/emtech-mit-2021-day-2-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

• EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/09/30/day-3-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

UPDATED on 9/27/2021

First day for Satwik Sunnam, Research Assistant 3 in our Team LPBI India is 9/27/2021

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/satwik-sunnam-research-assistant-3/

Assignment 1: Replacement to Dr. Pati on Cancer Volume 1, Chapters: 7,8,9,10,11,12

• Produce Hypergraph V1 – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
• Produce Tree Diagram Plots – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12

Assignment 2: Replacement to Ms. Amandeep Kaur on Genomics Volume 1, Chapters: 1-21

• Kaur completed Data preparation Chapters: 1,2,3,4,5 and 21
• Your assignment #2 include:
• Produce Data preparation for Chapters 6 -20
• Produce Deep Learning NLP for Chapters 1 to 21.

UPDATED on 9/22/2021

On 9/20 LPBI had issued the following Certificates:

First Certificate issued in the domain of

Medical Text Analysis with Deep Learning Natural Language Processing

Recipient: Yash Choudhary

On 9/17/2020, LPBI issued the following three Certificates in the domain of

IS, IT and Data Science

for the following Contributions:

Recipients: Abhisar Anand and Srinivas Sriram

for their contribution to IT system solution design for Data Extraction of Article Views

Problem definition:

To extract the views for each of the 6,000+ articles for different time periods. Must be done in a time-efficient manner that retrieves the necessary data for LPBI.

Conceptual solution:

Create a multiple-step process that involves web scraping the data in multiple processes to enhance the speed of the extraction, and use data analysis libraries in Python to format the data in the correct format.

Code Implementation: https://pharmaceuticalintelligence.com/sop-web-stat/

Recipients: Ethan Coomber

For his contributions to Text To Sound conversion of 150 Interviews with Scientific Leaders and for Twitter Analytics on LPBI’s two Twitter handles: @pharma_BI @AVIVA1950

UPDATED ON 9/6/2021

A long weekend ahead of us. Lots of good things to look forward to.

• Labor Day with all its meaning.
• For my culture, the High Holidays.

Blessed to be healthy, very creative and very productive.

What is New at LPBI Group:

1. We got this week all our 18 #booksin #medicinetranslated to #spanish
   • Cover Page
   • electronic Table of Contents
2. We created the first products using Wolfram #deeplearning
   Natural Language Processing #nlp
3. We made advances regarding launching a #blockchain#knowledge#graphdatabases for our
   • +6,080 scientific articles
   • 18 Books in Medicine (English and Spanish)
   • 100 e-Proceeding oh Top Tier Biotech Conferences
   • +6,000 Biological Images
4. Completed +150 conversion Text to Sound #TTS, I.e., Podcasts of Interviews with Scientific Leaders
5. Received the code for our Information System allowing for #data–#analytics#extractionof #articles #views per Year
   YES: +2MM Views – #bigdata 3.3 Giga Bytes !!!!
6. Made strides in further defining our platform for #syntheticbiologyin #drugdiscovery

#biotech #research #language #datascience #translation #ai

So much GOODNESS in one week

UPDATED ON 9/5/2021

Milestones reached on 3Q 2021

1. IT & Data Science Internship– LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
2. Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
3. Sign up agreement with SpeechKit– Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
4. ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contractand was paid by a Loan Aviva made to LPBI.  On 9/1/2021 wired the funds to cover the Invoice.
5. Instructions by Madison for all INTERNS on Deep Learning NLPusing Yash’s code – is almost ready
6. Proof-of-Concept for Cardiovascular text with Deep Learning NLP is ready by Yash using Adina’s Data preparation
7. PowerPoint SLIDE DECK for 2.0 LPBIis Ready – Text by Aviva and PPT by Srini and Abhisar
8. Completion of Internship Definition and Certificate Designon 9/2/2021 – Joint Work with Robin and Beth https://pharmaceuticalintelligence.com/certificate-1-year/
9. LPBI India is seeking additional Leadership to Dr. Saha and additional INTERNS for (a) Medical Text Analysis using Wolfram Deep Learning NLP and (b) Synthetic Biology Software for Drug Discovery
10. Synthetic Biology in Drug Discovery – Mission #4 for LPBI USA is Mission #2 for LPBI India: Updated by Dr. Williams on 8/20/2021. He will present on 9/14/2021. See update https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

UPDATED ON 8/31/2021

August 31, 2021 is a GREAT day for both organizations:

• Montero, Language Services, Madrid for COMPLETION of the Spanish Translation of LPBI Group’s EIGHTEEN Books in Medicine: Books Page Cover and electronic Table of Contents (eTOCs) per Volume
• LPBI Group, Boston for having the EIGHTEEN products of the Spanish Translation as agreed upon

This Spanish Translation serves our quest to

• (1) have the opportunity to REACH to the Medical communities in Spanish speaking countries and to Spanish speaking physicians and allied health professionals in the US, and
• (2) having the ability to re-Publish every book and every e-Seriesas a New Genre of Scientific Books in several new formats:

Series A, B, C, D, E – per each Series:

• Never published before as eTOCs of all Volumes in a Series
• Never published before in Spanish: Text or Audio
• Never published before in English Audio

All volumes in each Series – Bi-Lingual and Audio eTOCs

Cover Page and electronic Table of Contents

• Spanish & English Bi-Lingual eTOCs in Text – Today the FINAL products delivered
• Spanish eTOCs Translation in Audio [Text to Sound]
• English eTOCs in Audio [Text to Sound]

Per Volume for each of the 18 Books – New Genre of Scientific Books

• Part A: Bi-Lingual eTOCs: Spanish Audio and English Audio
• Part B: Results of Deep Learning Natural Language Processing with Domain Knowledge Expert Interpretation in [English text work-in-progress] and Spanish text to be translation of this English Text [Future Plan]
• Part C: Book original Editorials in English Audio [Text to Sound]

UPDATED ON 8/16/2021

Proof-of-Concept yielded LPBI’s SOPs on Natural Language Processing – How we will use Deep Learning NOT Statistical NLP !!!!!!!!

• Yash’s code.nb
• Deep learning methods
• 25 keywords
• Code file: code.nb
• pdf
• pdf

UPDATED ON 8/7/2021

#1:

LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate Program in Financial Modeling

https://pharmaceuticalintelligence.com/2021/08/07/lpbi-group-announces-5th-academic-internship-as-a-verifiable-certificate-in-financial-modeling-econometrics-as-one-semester-or-as-one-year-program-open-to-undergraduate-and-mba-students/

These are the FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs One year or One semester: Volunteer base

1. NLP – Medical Text Analysishttps://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
2. Synthetic Biology in Drug Discovery targeting Galectinshttps://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
3. IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects https://pharmaceuticalintelligence.com/2021/07/11/plan-for-sops-for-lpbi-groups-it-data-science-management-projects/Informations technology & systems of LPBI: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images. All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence: Twitter Analytics +1,100 followers of two handles and LinkedIn ~8,000 1st degree connections of LPBI’s Founder, including +500 CEOs.
4. BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].

#2:

LPBI and Linguamatics are schedule to meet with

• LPBI’s and Linguamatics’ potential NEW two clients:
• Director of Research at an HMO &
• COO/CEO of a Healthcare INSURER on
• August 18, 2021 at 3PM EST

#3:

LPBI’s GLOBAL Monthly Zoom Meeting is on August 10, 2021 at11AM EST to 4PM EST – Please ATTEND

Presentations by

• Williams
• ALL 2021 SUMMER INTERNS
• Aviva
• External Presenter TBA

AGENDA for August 10, 2021 at 11AM EST to 4PM EST

Link sent on 8/9 at 5PM and on Link REMINDER on 8/10 at 9AM

https://pharmaceuticalintelligence.com/calendar/

UPDATED ON 8/3/2021

LPBI Team in LPBI India include: 3,4,6,7,8,10,11

 

UPDATED ON 7/26/2021

We are excited to have new Interns coming onboard with inquisitive minds and motivation to learn new skills and invest in their careers by Experientional  learning methods.

LPBI Group runs FOUR MAJOR INTERNSHIPS: Volunteer base

1. NLP – Medical Text Analysis
2. Synthetic Biology in Drug Discovery targeting Galectins
3. IT Project and Administration of IP Asset Classes: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images
4. BLOCKCHAIN Architecture design: Interface of NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY.

Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN.

• NLP-Blockchain IT Infrastructure is needed.
• The NLP inferences are part of a graph database
• In BurstIQ case is a LifeGraph – the larger architecture of the system functionality.

LPBI has you and your education goals in mind:

• We Offer esteemed Affiliation, Mentorship by Scientists
• NEW skills development in NLP, ML, AI applications to Medical Text Analysis
• Skills in Synthetic Biology for Drug Discovery
• References and Resume paragraph on accomplishments and goals during the INTERNSHIP
• Opportunity to contribute to Publications and Podcasting
• Explorations of opportunities in Life Sciences in the US

UPDATED ON 7/26/2021

LPBI’s VALUATION is the stream of INNOVATIONS to date while being DEBT free:

1. 4/2012 – LPBI is the Launcher of Scientific Curation Methodology for the e-Scientific Publishing industry https://pharmaceuticalintelligence.com/As late as in 2016 no big publisher, i.e., Elsevier, John Wiley had curation-based publications: Journal, Books, e-Proceedings, Gallery of +6,000 Biological Images as an IP asset class

• At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers

2. 6/2013 – LPBI was the Publisher of the 1^ste-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
3. 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine
4. On Amazon.com on 7/2021 – e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads
5. LPBI launched NLP in 1/2020. Linguamatics/IQVIA performed NLP on 33 articles and 20 Biological Images. RESULTS:  +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:

• Gene-Disease
• Gene-Drug
• Disease-Drug
• These results were presented to a Healthcare Insurer, SLC, UT on 7/13/2021

6. LPBI and BurstIQ are architecting NOW the first NLP-Blockchain IT infrastructure in existence

• Linguamatics did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER

7. On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, ABI Lab and SBH Sciences, Inc., Natick, MA
8. On 7/25/2021 – LPBI announced it will have the NEWLY to be published BioMed e-Books As ANEW Publishing GENRE of SCIENTIFIC BOOKS
   • Bi-Lingual eTOCs, English & Spanish with Montero Language Services, Madrid and Content promotion by GTO, Madrid
   • NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and Audio: Spanish and other
   • Original English Book – Only Editorials(Preface, Introductions, Summaries and Epilogue] because the Bi-Lingual part is the eTOCs of the e-Book
   • New architecture of MULTIMEDIA SCIENTIFIC e-Books

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

9. Based on the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/we are building

• Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up alliances: Alliances are Labor component and LPBI is Materials – 25% on top paid by the B2B customer
• B2C on Blockchain will use the Price List.

UPDATED ON 7/19/2021

Official launch of LPBI India – Zoom meeting

On July 19, 2021 at 11AM EST

UPDATED AGENDA

 

Member Name	Geographical region in India Or Place of Birth in India if now outside of India	Distance from New Delhi	LANGUAGES
Dr (Lt Col) Vivek Lal	Ambuja Nagar, Kodinar (Sasan-Gir) Gujarat.	1300 kms	English, Hindi
Yash Choudhary	Dewas (Madhya Pradesh)	800 kms	English, Hindi
Dr. Premalata Pati	Bhubaneswar, Odisha	1764 kms	English, Hindi, Odia
Dr. Sudipta Saha	Kolkata, West Bengal	1500 kms	English, Hindi, Bengali
Dr. Ajay Gupta	Place of birth: New Delhi	0	English, Hindi
Amandeep Kaur	Kolkata, West Bengal	1500 kms	English, Hindi, Punjabi, Bengali
Indraneel Ghosh	Vadodara, Gujarat	1025 kms	English, Hindi, Bengali, Marathi, Gujarati
Aditya Bahl	Lucknow, UP	500	English, Hindi, Punjabi
Srinivas Sriram	Place of Birth: Chennai, Tamil Nadu	2,187 kms	English, Tamil
Abhisar Anand	Place of Birth: Muzaffarpur, Bihar	1,042 kms	English, Hindi

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA

is Launching LPBI India on 7/19/2021

LPBI India Official Launch

on Zoom on July 19, 2021 at 11AM EST

• I wish to invite you to attend this Zoom meeting using the Zoom Link, above

LPBI India LAUNCH

is on Monday July 19, 2021 at 11AM EST

Aviva – Founder 1.0 LPBI and 2.0 LPBI

• Justifying the Launch of LPBI India todayis the Interaction between LPBI USAand LPBI India which is taking place multiple times every day
• Senior level executive talent in India expressed interest to JOIN LPBI USA while living in India
• It was Dr. Lal and Dr. Ghosh interest in joining LPBI USA that impacted Aviva’s Decision toward the Launch of LPBI India: Leadership + Professional Staff
• Interactions among all members across Indiais mostly encouraged
• We are preparing a MAP with all the locations in India of our VIRTUAL organization
• We are a community of inclusion and excellence challenging and aspiring for expression and growth of the best of our abilities without borders and/or pre-determinants of any kind: age, race, religion or gender
• Interactions with Alumni of LPBI USAis mostly encouraged – we are very proud of each of you,

Congratulatory Remarks, each presenter from their own perspective:

1. LPBI USA Board member,  Marc W. Feldman, Stanford University [7/18/2021 – Medical Emergency] <<< – WE WISH YOU SPEEDY RECOVERY, next Global Zoom on August 10, 2021 – Congratulatory remarks will be delivered
2. LPBI USA Board member,   Stephen J. Williams,Temple University
3. Ajay Gupta of UC, Irvine, LPBI USA, External Scientific Relations
4. Aditya Bahl, MBA, LPBI USA, External Business Relationsto LPBI USA since 1/2020. Mr. Bahl is ex-Novastis and ex-J&J, the Founding Director at RAS Life Science Solutions, based in Frankfurt, Germany
5. Raphael Nir, Founder, ABI Lab and President, SBH, Inc in Natick, MA – We will have in 4Q’2021 a JOINTmeeting dedicated to Mission #2, below

  

Mission #1:

Medical Text Analysis with Natural Language Processing (NLP), Machine Learning (ML), Artificial Intelligence (AI)

 

The Medical Text includes FOUR corpuses of content created by the Team at LPBI USA since 4/2012:

1. Scientific Curation Articles published in our Open Access Journal http://pharmaceuticalintelligence.com

N = +6,070, Views = +2Million, with an ontology of +730 categories of Research in the Life Sciences, Medicine, Pharmaceutics and Healthcare

2. 18 e-Books in Medicine https://lnkd.in/ekWGNqA

128,000 page download on Amazon.com – Cover Pages and electronic Table of Contents (eTOCs) of the 18 books are been translated to Spanish in Madrid, now

3. 100 e-Proceedings of Global Medical and Biotech Conferences generated in Real Time, 2013 – 2021 https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
4. +6,200 Biological Images with text legend in use by the +6,000 articles – in the Media Galleryof LPBI on WordPress.com cloud. Mission #1 has increased the number of Biological images from 5,100 to +6,200

At LPBI India, been considered for the Leadership function for Mission #1: Dr. Vivek Lal, MD

STRATEGIC PLAN for Mission #1

For scaling up the Text Analysis of these 3.3 Giga Bytes of data we are in alliance with Linguamatics/IQVIA, London https://www.linguamatics.com/what-text-mining-text-analytics-and-natural-language-processing

• We jointly presented their NLP results on our content in oncology to a Top HMO/Healthcare Insurer in UT on July 13, 2021. We are invited for additional meetings with both organizations: the HMO and the Healthcare Insurer
• LPBI USA developed a ten-phase Protocol for our own content been subjected to Medical Text Analysis with NLP, ML, AI using Wolfram language for BioSciences

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/

• LPBI India will be involved in all of the ten-phase Protocol in using NLP, ML, AI
• LPBI is in alliance with BurstIQ, Denver, CO https://www.burstiq.com/for Blockchain design for a Transactions Network for Content monetization: B2B and B2C. That process involve Indexing and data migration. LPBI India will play a role in these tasks as well

 

Mission #2:

Applications of Synthetic Biology Software to Galectins for design of new drug molecules.

• Collaboration with   Raphael Nir of ABI Lab and SBH, Inc in Natick, MA. We will have in 4Q’2021 a dedicated meeting on Mission #2.
• LPBI India will play a role in these tasks, please review:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877766/

• LPBI USA has interest in Synthetic Biology Software for Drug Discoveryand has two scientists with expertise in Galectins as therapeutic targets
• Scientists love Synthetic Biology – designing drug molecules using Software – igem.org

https://igem.org/Software

A repository of open source software tools.

Community driven data exchange standards.

Specific software frameworks built explicitly for synthetic biology.

• LPBI USA will have a DropBox Folder with all the Synthetic Biology Software accessible toLPBI India
• Mentorship and training will be offered by LPBI USA

At LPBI India, been considered for the Leadership function for Mission #2: Dr. Indraneel Ghosh, PhD

STRATEGIC PLAN for Mission #2

• We will have in 4Q’2021 a JOINT meeting between LPBI USA, LPBI India with   Raphael Nir of ABI Lab and SBH, Inc in Natick, MA on Mission #2.
• A collaboration between Dr. Ghosh and Dr. Nir is expected

 

AGENDA

Zoom of LPBI INDIA Launch on Monday July 19, 2021 at 11AM EST

PRESENTATIONS

• Stephen J. Williams,LPBI USA, Chief Scientific Officer and Board Member is with LPBI USA since 9/2012 will have presentations
• Aviva will have presentations

Senior Level at LPBI India:

• LPBI India TEAM Members BIO Presentations: Each of the members of LPBI Indiawill present their BIO in <5 minutes, starting with

Dr. Sudipta Saha, PhD Prof. at Amity University, New Delhi. Dr. Saha is with LPBI USA since 9/2012, Expert, Author and Co-Editor

http://www.amazon.com/dp/B08VTFWVKM

Available on Amazon.com since 2/2/2021

https://www.amazon.com/dp/B075CXHY1B

On Amazon.com since September 4, 2017

Dr. Vivek Lal, MD, COO, Ambujanagar Multi-specialty Hospital, Ambujanagar, Dist. Gir-Somnath, Gujarat, India.

• Paper collaboration with Dr. Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN on 9/2013, article has ~15,000 e-Readers https://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/

Dr. Indraneel Ghosh, PhD – Weizmann Institute PhD, 2000-2007, Hebrew speaker

• CV on LPBI USA Website – Work-in-Progress

https://pharmaceuticalintelligence.com/contributors-biographies/inventors-biologics/indraneel-ghosh-phd-inventor-biologics-lead-on-lpbi-india-synthetic-biology-drug-discovery-team/

Dr. Ajay Gupta of UC, Irvine, Scientific Advisor to LPBI USA, frequent presentation on LPBI’s SCIENCE SIDE – Global Monthly Zoom

• Ten Minuteson on Clinical Trials for RAMATROBAN  – Opportunities for Collaboration between His Company in USA & LPBI India, Dr. Lal’s Hospital and other Hospitals in India

Ramatroban is a thromboxane receptor antagonist. It is also a DP₂ receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Wikipedia

ChemSpider ID: 110413

Molar mass: 416.47 g·mol⁻¹

Formula: C₂₁H₂₁FN₂O₄S

Members of Technical Staff (MTS) at LPBI India & LPBI USA:

• All LPBI India MTS currently working on Mission #1 and
• All LPBI USA MTScurrently working on IT/Data Science Projects
  • will be invited to considered Mission #2.
• An Up-to-date CV in Biological SciencesREQUIRES DEMONSTRATION of making contributions with mentorship in both areas: Mission #1 and Mission #2

LPBI India and LPBI USA MTS – BIO Presentations: PostDocs, Masters and Students will present their Bios in <4 minutes:

• Pati,PostDoc. NLP – One year Academic Training
• Kaur, MSc. NLP – One year Academic Training
• Choudhary,Student IITK – Summent intern, 6/15/ – 8/15/2021
• Sriram,Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
• Anand, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
• Ethan Coomber, Middlebury College, VT – Research Assistant 3, Text to Audio Conversion and Twitter Analytics
• Vaishnavee Joshi, MSc – Joining LPBI India on 8/15/2021

Alumni of LPBI USA are invited to join us on Monday, July 19, 2021, 11AM EST

• Probodh Kandala, PhD, Regulatory Affairs Manager @ IQVIA Biotech; Drug Development Leader, Expert, Author, Writer with scientific reporting articlesin multiple of LPBI e-Books, chiefly Cancer and Immunology
• Ritu Saxena, PhD, Astellas Pharma US, Co-Editor, LPBI’s Series C, Volume 1 http://www.amazon.com/dp/B013RVYR2K
• Aviral Vatsa, MD, NHS Education for Scotland, Co-Editor,LPBI’s Series A, Volume 1 http://www.amazon.com/dp/B00DINFFYC
• Aashir Awan, Research Scientist, Bristol Myers Squibb, Expert, Author, Writer (EAW) for PharmaceuticalIntelligence.com
• Anamika Sarkar,Regeneron, EAW at LPBI 2014-2016

Alumni of LPBI USA:  Please catch up with us, we thank you for your contributions made to LPBI USA

• Please review our portfolio of Intellectual property of 10 Asset Classes in 2021 https://pharmaceuticalintelligence.com/2019-vista/
• Please review our six strategies for 2021-2025https://pharmaceuticalintelligence.com/vision/

@@@@@@@@ ALL NEED TO PLAN TO ATTEND 7/21, 2021 – LPBI USA – BUSINESS SIDE

UPDATED ON 7/5/2021

ANNOUNCEMENT of NEW SUMMER INTERN in Medical Text Analysis with NLP – Cardiovascular Content – 2021 Summer Internship in NLP – LPBI India

Yash Choudhary, Research Assistant 3

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/yash-choudhary-research-assistant-3/

UPDATED ON 6/20/2021

ANNOUNCEMENT of NEW SUMMER INTERN

Ethan Coomber, Research Assistant III, Data Science and Podcast Library Development 

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/ethan-coomber-research-assistant-iii-data-science-and-podcast-library-development/

UPDATED ON 6/16/2021

ANNOUNCEMENT of TWO NEW SUMMER INTERNS who also plan to start in 9/2021 the LPBI 2021-2022 Academic Training in NLP for Medical Text Analysis

Abhisar Anand, Research Assistant I

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/abhisar-anand-research-assistant-i/

Srinivas Sriram, Research Assistant I

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/srinivas-sriram-research-assistant-i/

UPDATED ON 5/17/2021

LPBI management wants you to be PROUD about

1. The Spanish Translation 18 volumes (Cover Pages, eTOCs all books)  – Alliance with Montero Language Services, Madrid, Spainand their’s Marketing Communication Agency for

1.1  Plans for Content Promotion in Spanish Speaking Countries

1.2  Other Marketing Communications needs of 2.0 LPBI

2. NLP plan for IP Asset Classes I,II, III, V – Consideration of Alliance with Linguamatics/IQVIAfor Indexing of +6,000 articles 
3. Blockchain Transaction Network for Content monetization system design for Digital Store in a Healthcare Digital Marketplace: B2B, B2C – Collaboration with BurstIQ
4. Insurer Contactand Proof-of-Concept READY for joint Presentation with Linguamatics/IQVIA
5. IB in NYC preparing Proposal for LPBI becoming their Client
6. Working with few Sources to identify C-Suite new Members

• New Management
• New Ownership
• New Company – incorporation as ‘C’

UPDATED ON 5/5/2021

One Pager for 2.0 LPBI Group

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

• Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
• From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
• From Open Access we will transition to Blockchain transaction networks.
• From Digital Cloud-based biographies we will create audio and video Podcasts
• From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships

Our Transformational transition is two dimensional:

• Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
• Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.

We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/

5/5/2021

LPBI Group’s Organizational Chart was updated on 5/5/2021

4/24/2021

REMINDER of important articles in our repository

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL.  Author and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/thriving-at-the-survival-calls-during-careers-in-the-digital-age-an-age-like-no-other-also-known-as-digital/

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

4/14/2021

Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD

https://pharmaceuticalintelligence.com/2021/04/14/mechanism-of-thrombosis-with-astrazeneca-and-j-j-vaccines-expert-opinion-by-kate-chander-chiang-ajay-gupta-md/

2/26/2021

2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

Real Time coverage: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/02/26/2021-virtual-world-medical-innovation-forum-mass-general-brigham-gene-and-cell-therapy-virtual-may-19-21-2021/

2/16/2021

Announcing two new members of the Medical Text Analysis with Machine Learning

Premalata Pati, PhD, PostDoc in Biological Sciences, Medical Text Analysis with Machine Learning

https://pharmaceuticalintelligence.com/contributors-biographies/postdoctorants-computer-science-pharmaceutical-sciences-biological-sciences/premalata-pati-phd-postdoc-in-pharmaceutical-sciences-medical-text-analysis-with-machine-learning/

Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder

https://pharmaceuticalintelligence.com/contributors-biographies/associates/amandeep-kaur-bsc-msc-9exp-5-2021-research-associate-2-medical-text-analysis-and-it-infrastructure-python-coder/

2/12/2021

Need for Global Response to SARS-CoV-2 Viral Variants

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/02/12/need-for-global-response-to-sars-cov-2-viral-variants/

Rise of a trio of mutated viruses hints at an increase in transmissibility, speeding the virus’ leaps from one host to the next

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/02/01/rise-of-a-trio-of-mutated-viruses-hints-at-an-increase-in-transmissibility-speeding-the-virus-leaps-from-one-host-to-the-next/

2/8/2021

LIVE – 50th Annual Lewis S. Rosenstiel Award to Katalin Karikó and Drew Weissman for work on messenger RNA, modification of Nucleic Acids applied in the development of COVID-19 Vaccines

Reporter & Real Time Coverage on 2/8/2021:

• Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

https://pharmaceuticalintelligence.com/2021/01/22/50th-annual-lewis-s-rosenstiel-award-to-katalin-kariko-and-drew-weissman-for-work-on-messenger-rna-modification-of-nucleic-acids-applied-in-the-development-of-covid-19-vaccines/

2/5/2021

Today Series D: Volume 4, LPBI’s #18 Volume is LIVE

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases and Endocrinology

 

VOLUME 1: Metabolic Genomics and Pharmaceutics.

(Series D: BioMedicine & Immunology) Kindle Edition

On Amazon.com since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0

VOLUME 2: Infectious Diseases and Therapeutics

and

VOLUME 3: The Immune System and Therapeutics

(Series D: BioMedicine & Immunology) Kindle Edition. On Amazon.com since September 4, 2017

https://www.amazon.com/dp/B075CXHY1B

VOLUME 4: Human Reproductive System, Genomic Endocrinology and Cancer Types

(Series D: BioMedicine & Immunology) Kindle Edition.

On Amazon.com since February 2, 2021

http://www.amazon.com/dp/B08VTFWVKM

 

2/3/2021

Check our podcasts

• Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-sudipta-saha-phd-interview-by-gail-s-thornton-phdc-narrators-voice-gail-s-thornton-phdc/

• Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

• Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-prof-marcus-w-feldman-phd-biology-department-stanford-university-interview-by-gail-s-thornton-phdc/

• Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/partners-in-health-and-biz-radio-interview-with-aviva-lev-ari-ph-d-r-n-stephen-williams-ph-d-and-irina-robu-ph-d-on-5-2019-on-topic-of-3d-medical-bioprinting-technology-a-revolution-in-med/

2/1/2021

Milestone achieved today:

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical 

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Thought on the transition

One Possible Strategy for an Acquisition is via a SPAC

https://pharmaceuticalintelligence.com/2021/01/30/one-possible-strategy-for-an-acquisition-is-via-a-spac/

1/8/2021

PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views

Hanoch Lev-Ari, PhD and Aviva Lev-Ari, PhD, RN

Total number of articles viewed in any given year depends on:

1. The overall Average Article-Viewing Profile (AAVP)
2. The number of articles published in the year of interest, and in each one of the preceding years.

In statistics, the article viewing process is known as a “marked point process”: the time-instants of article publication are the events described by the point process, while the “mark” is the subsequent process of viewing each particular article, ongoing from the moment of publication into the future over many years. The article viewing process is assumed to be statistically-independent from the publication time-instants.

https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

1/6/2021

2.0 LPBI Team Welcomes to our Medical Text Analysis Team

Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder

https://pharmaceuticalintelligence.com/contributors-biographies/associates/amandeep-kaur-bsc-msc-9exp-5-2021-research-associate-2-medical-text-analysis-and-it-infrastructure-python-coder/

 

REUTERS NEXT (Jan 11-14) kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/01/06/reuters-next-jan-11-14-kicks-off-2021-by-gathering-global-leaders-and-forward-thinkers-to-reimagine-solutions-to-the-challenges-the-new-year-brings/

1/3/2021

Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/

Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/01/01/announcing-strategic-transition-from-1-0-lpbi-to-2-0-lpbi-on-1-1-2021-new-management-and-new-technical-opportunities/

1/1/2021

Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

Author: Aviva Lev-Ari, PhD, RN

For your New Opportunity in 2021:

• Management,
• MarkComm and
• Scientific/Technical

CONTACT

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

 

DESCRIPTION

https://pharmaceuticalintelligence.com/vision/

 

Announcement

Strategic Transition from 1.0 LPBI to 2.0 LPBI on

 1/1/2021

 

We have transitioned from

• 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020

to

• 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS. A new company profile, 2021 – 2025

Our New NEEDS in Business Development and M&A – Pursue with results:

• Equity Sharing based

Opportunities Map in the Acquisition Arena

Our New NEEDS in Marketing Communication, Media & PR – Produce new Digital mediums

• Equity Sharing based

1. The Announcement of 2.0 LPBI Launch
2. NEW Website for 2.0 – Initiative #2
3. Podcast – Strategy #4 – we wish to publish 2 Podcasts per quarter
4. Planning Advertisement for Amazon Books using Amazon Advertising
5. NEW documentation on Strategy #2 – Monetization of Journal Articles
6. NEW documentation on Strategy #2 – Monetization of other IP Asset Classes
7. NEW documentation on Strategy #1, #3, #6
8. Reporting on developments in Strategy #5: Joint Ventures & Partnership

Our New Scientific/Technical Opportunities in Natural Language Processing (NLP), Machine Learning (ML) and Artificial Intelligence (AI)

 

Seeking 10 Students INTERNS for a major Medical Text Analysis using NLP, ML, AI

This is a ONE year VIRTUAL STUDENT INTERNSHIP for

• Computer Science & Biological Sciences or
• PreMed students
• PostDocs will develop the interpretation for the hyper-graphs

This internship is not fee for service – but voluntary and offers

• Mentorship by Scientists
• Letter of recommendation
• Opportunity to publish with lead authors
• Hands on experience with software
• Opportunities to present in corporate business meetings
• Scientific Career guidance
• Access to contacts in Academe and Industry

DESCRIPTION

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

https://pharmaceuticalintelligence.com/2021/01/01/announcing-strategic-transition-from-1-0-lpbi-to-2-0-lpbi-on-1-1-2021-new-management-and-new-technical-opportunities/